Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
Submitted by
admin
on January 25, 2019 - 11:53am
Source:
CP Wire
News Tags:
Coherus Biosciences
AbbVie
Humira
CHS-1420
biosimilars
Headline:
Coherus BioSciences Announces Settlement with AbbVie to Market its Humira Biosimilar Candidate
snippet:
Coherus’ license period in the U.S. commences on December 15, 2023
Coherus will pay royalties to AbbVie
The company has six candidates in development
Do Not Allow Advertisers to Use My Personal information
